Slide 1: Driving innovation & growth
Driving innovation & growth Severin Schwan | CEO Roche Group Octavian Conference, 13 January 2022
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Providing solutions for COVID-19; R&D; Growth opportunities; Outlook
Providing solutions for COVID-19 Continued investment in R&D Growth opportunities Outlook 3
Slide 4: Roche's contribution battling the pandemic
Roche’s contribution battling the pandemic > 1 million hospitalized patients received Roche’s treatments = positive Ph III results Overview: not all COVID-19 related developments and health solutions captured; EUA=emergency use authorization; RUO=Research use only; * through GenMark acquisition 4
Slide 5: Global Monthly Reported Cases: COVID scenarios
Uncertainty on how Delta & Omicron will impact medium-term and evolution of COVID Example scenarios and key assumption drivers (not exhaustive) Scenario A: COVID steady state ● Delta & Omicron drive near-term caution and higher vaccination rates Global Monthly Reported Cases ● Vaccine and/or disease
Slide 6: Roche group: Strong underlying business momentum to continue
Roche group: Strong underlying business momentum to continue % CER 1st wave 2nd wave 3rd wave +60% Pharmaceuticals +50% +55% +48% +50% • New products with strong momentum; impact from +40% biosimilars to flatten +40% +32% +28% +29% +30% +25% • Major launches in ophthalmology and hematology +18% +20%
Slide 7: Strong portfolio rejuvenation and diversification
Strong portfolio rejuvenation and diversification Diagnostics Diagnostics Diagnostics CHFm 4,856 CHFm 5,562 CHFm 9,042 AHR AHR AHR HY 2011 HY 2016 HY 2021 Pharma Pharma Pharma CHFm 16,815 CHFm 19,460 CHFm 21,671 Diagnostics Ophthalmology Immunology Neuroscience Other pharma Metabolism/Bone Oncology
Slide 8: Providing solutions for COVID-19; R&D; Growth opportunities; Outlook
Providing solutions for COVID-19 Continued investment in R&D Growth opportunities Outlook 8
Slide 9: Roche group: Reallocating resources to strengthen innovation
Roche group: Reallocating resoures to strengthen innovation Continued investments into R&D to drive future growth & medical advances Pharma R&D investment allocation (% of OPEX) • Re-allocate resources into R&D while working on and protecting profitability Others • All departments of Roche aligned o
Slide 10: Pharma: Broadest set of technology platforms
Pharma: Broadest set of technology platforms * List of pipeline molecules shown below is not complete; Molecules in the orange box are developed in Oncology 10
Slide 11: Recent deals and partnerships
Recent deals and partnerships1 Accelerate drug discovery and driving personalized healthcare New agreements focused on High disease burden / Promising targets / Novel enabling techologies / Decision support 1 Non-exhaustive and illustrative overview of deals and partnerships signed over recent years
Slide 12: Pharma digital strategic priorities
Pharma digital strategic priorities Clinical Production & Pre-clinic Registration Access Diagnosis Treatment development Supply Research & development Production & supply chain Medicine augmentation Accelerate and de-risk early-stage Today Blockbuster drugs assets in research via automation, Past mo
Slide 13: Providing solutions for COVID-19; R&D; Growth opportunities; Outlook
Providing solutions for COVID-19 Continued investment in R&D Growth opportunities Outlook 13
Slide 14: 6 pivotal adjuvant read-outs expected in 2022
6 pivotal adjuvant read-outs expected in 2022 Moving earlier in the treatment schedule Outcomes by cancer type and stage Ph III adjuvant trial program for Tecentriq & Alecensa at diagnosis 1 • Early detection technologies and increasing screening will allow for earlier treatment • Early treatment in
Slide 15: Tiragolumab with 9 pivotal trials initiated, 4 readouts in 2022
Tiragolumab with 9 pivotal trials initiated, 4 readouts in 2022 Positive OS data in 1L NSCLC presented Ph II (CITYSCAPE) results: Ph III trial program for tiragolumab Tiragolumab + Tecentriq in 1L PDL1+ NSCLC (n=58) Overall survival for TPS≥ 50% Indication Ph 1 Ph 2 Ph 3 1L NSCLC: PD-L1 high SKYSCRA
Slide 16: Neuroscience portfolio differentiated on targets and technologies
Neuroscience portfolio differentiated on targets and technologies Ph III studies in Alzheimer’s to read out in 2H 2022 Ph I (4 NMEs) Ph II (7 NMEs) Ph III (3 NMEs, 1LE) Launched (3) UBE3A LNA prasinezumab gantenerumab Ocrevus RG6091 Angelman syndrome RG7935 RG1450 RG1594 Parkinson’s Alzheimer’s MS s
Slide 17: Broadening and deepening the ophthalmology pipeline
Broadening and deepening the ophthalmology pipeline Building a global ophthalmology franchise Anti-HtrA1 mAb Digital solutions & Faricimab DutaFabs + PDS in GA new technologies • First Roche intravitreal implant • New dual MOA: Anti-VEGF/ • DutaFabs enable • Novel pathway in GA • Develop digital too
Slide 18: Providing solutions for COVID-19; R&D; Growth opportunities; Outlook
Providing solutions for COVID-19 Continued investment in R&D Growth opportunities Outlook 18
Slide 19: Our replace and extend strategy is progressing well
Our replace and extend strategy is progressing well Entering new Replace ongoing franchises franchises Strong news flow ahead (data readout) tiragolumab (SKY-1) Oncology: in PDL1-high NSCLC Gazyva, Tecentriq (mUC, SCLC, tiragolumab (SKY-2) Venclexta, HCC, mM), in 1L ES-SCLC MabThera/Rituxan Polivy,
Slide 20: Positive outlook re-iterated
Positive outlook re-iterated Pharma late-stage NMEs and Dia launches faricimab, mosunetuzumab, glofitamab, tiragolumab, gantenerumab, giredestrant, crovalimab, fenebrutinib, rhPTX-2, SRP-900, etc. cobas 6800/8800, cobas 5800, cobas pure, cobas pro (high throughput), cobas Mass Spec, cobas Liat, etc.
Slide 21: Doing now what patients need next
Doing now what patients need next 21